WINTON GROUP Ltd Takes Position in Personalis, Inc. $PSNL

WINTON GROUP Ltd purchased a new stake in shares of Personalis, Inc. (NASDAQ:PSNL) in the second quarter, HoldingsChannel.com reports. The firm purchased 37,013 shares of the company’s stock, valued at approximately $496,000.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Merck & Co. Inc. purchased a new position in Personalis in the 2nd quarter valued at about $188,202,236. BlackRock Inc. purchased a new stake in shares of Personalis during the second quarter worth about $94,905,000. Bank of America Corp DE purchased a new stake in shares of Personalis during the second quarter worth about $24,395,000. AIGH Capital Management LLC purchased a new stake in shares of Personalis during the second quarter worth about $22,981,000. Finally, Next Century Growth Investors LLC acquired a new position in shares of Personalis in the fourth quarter worth about $4,970,000. Institutional investors and hedge funds own 61.91% of the company’s stock.

Personalis Stock Performance

NASDAQ:PSNL opened at $16.10 on Wednesday. The company has a market capitalization of $1.69 billion, a price-to-earnings ratio of -14.77 and a beta of 2.31. Personalis, Inc. has a one year low of $4.95 and a one year high of $18.89. The stock has a 50-day simple moving average of $14.92 and a 200 day simple moving average of $10.69.

Personalis (NASDAQ:PSNL) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.04). Personalis had a negative net margin of 153.84% and a negative return on equity of 46.47%. The firm had revenue of $22.36 million for the quarter, compared to analyst estimates of $16.69 million. On average, equities research analysts forecast that Personalis, Inc. will post -1.07 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO Aaron Tachibana sold 4,982 shares of the firm’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $14.00, for a total transaction of $69,748.00. Following the transaction, the chief financial officer directly owned 198,833 shares in the company, valued at $2,783,662. This trade represents a 2.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher M. Hall sold 100,000 shares of Personalis stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $15.08, for a total transaction of $1,508,000.00. Following the completion of the transaction, the chief executive officer directly owned 235,986 shares of the company’s stock, valued at approximately $3,558,668.88. This represents a 29.76% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 256,233 shares of company stock valued at $3,568,236 over the last quarter. Company insiders own 4.20% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently commented on PSNL. TD Cowen reissued a “buy” rating on shares of Personalis in a report on Wednesday, July 15th. Wall Street Zen downgraded Personalis from a “hold” rating to a “sell” rating in a report on Saturday, June 13th. Morgan Stanley upped their target price on Personalis from $9.00 to $13.00 and gave the company an “equal weight” rating in a research report on Thursday, July 9th. BTIG Research increased their target price on Personalis from $11.00 to $16.25 and gave the company a “buy” rating in a research note on Monday, July 20th. Finally, Lake Street Capital downgraded shares of Personalis from a “buy” rating to a “hold” rating and set a $16.25 price target for the company. in a research report on Monday, July 20th. Four equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $14.54.

About Personalis

Personalis, Inc is a genomics company focused on precision oncology and advanced molecular testing. The company develops and commercializes genomic products designed to help identify, monitor and characterize cancer, supporting more informed treatment decisions and the development of targeted therapies.

Its offerings include tissue- and blood-based tumor profiling, liquid biopsy testing and immune profiling. Personalis’ technologies are designed to detect and track tumor-derived signals, evaluate genomic alterations and provide insights into the interaction between cancer and the immune system.